Next, to clarify the effects of ADAM9 genetic polymorphisms on the clinicopathological status of PCa, we examined factors such as pathologic staging, pathologic Gleason grade groups, clinical staging, tumor invasion statuses, and D'Amico classification. This evidence concerns the gene ADAM9 and posterior cortical atrophy.